Semax

Semax Dragon Pharma — Overview

Semax Dragon Pharma is a synthetic heptapeptide nootropic supplied at 5 mg per lyophilized vial. Its sequence — Met-Glu-His-Phe-Pro-Gly-Pro — is built on the ACTH(4-7) fragment of adrenocorticotropin, extended at the C-terminus by Pro-Gly-Pro to prevent rapid enzymatic degradation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside Selank, Semax is approved in Russia for the treatment of cognitive impairment, ischemic stroke recovery, and neurasthenia, and has been in clinical use since the 1990s. In performance and cognitive optimization contexts it is the primary stimulatory nootropic peptide — producing alert, activated, goal-directed focus and drive through BDNF upregulation, melanocortin receptor activation, and enhancement of dopaminergic and serotonergic neurotransmission.

Where Selank calms and stabilizes, Semax energizes and activates. It is the compound of choice when the goal is cognitive output, motivation, learning speed, and mental drive rather than anxiety relief. It does not suppress the HPTA, causes no dependence, and produces no sedation or motor impairment at any standard dose. A 5 mg Dragon Pharma vial reconstituted in 5 mL bacteriostatic water yields 25 × 200 mcg doses at 1 mg/mL — sufficient for a full 3–4 week nootropic protocol at once-daily dosing. Semax is available at Steroid Warehouse alongside its complementary anxiolytic partner Selank for users building a comprehensive cognitive enhancement stack.

About the Compound: Semax

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic derivative of adrenocorticotropin fragment ACTH(4-7), which is the minimal biologically active core sequence responsible for ACTH's cognitive and neuroprotective effects independent of its cortisol-stimulating function. The ACTH(4-7) tetrapeptide has an extremely short plasma half-life of 2–3 minutes due to rapid cleavage by membrane-bound aminopeptidases; Semax addresses this by appending the Pro-Gly-Pro tripeptide at the C-terminus, which sterically blocks the primary cleavage sites and extends the effective biological window to 20–30 minutes in plasma and several hours at the tissue level following subcutaneous or intranasal administration.

Semax activates the melanocortin receptor system — specifically MC2R and MC4R, which are expressed in the brain, adrenal cortex, and peripheral tissues. MC4R activation in the hypothalamus and limbic system drives the motivational, attentional, and arousal-promoting effects that define Semax's experiential profile. Simultaneously, Semax robustly upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus, prefrontal cortex, and striatum; this neurotrophic effect is the molecular basis for the cumulative nootropic improvement in memory consolidation and learning that builds over 2–3 weeks of consistent use. The compound also modulates dopamine and serotonin turnover in limbic and cortical regions, contributing to the drive, mood-elevation, and motivation components of its profile.

Importantly, Semax does not stimulate cortisol release despite acting on ACTH-derived sequences; the cortisol-stimulating activity of full ACTH requires the ACTH(1-24) N-terminal sequence, which is absent from Semax. The compound does not activate the HPA axis in the cortisol-releasing sense, does not suppress the HPG axis, and has no androgenic or estrogenic activity. It is pharmacologically clean in hormonal terms and can be used at any stage of a hormonal protocol without interference.

What Semax Does

• Acute cognitive activation — focus, attention, and mental drive — Semax produces a distinct state of alert, goal-directed cognitive engagement that users describe as clean mental energy without the anxious edge of stimulants; melanocortin MC4R activation in the prefrontal cortex and limbic system increases sustained attention capacity, reduces mind-wandering, and sharpens executive function; the effect is present from the first dose and peaks 1–2 hours after injection; unlike caffeine or amphetamine-class stimulants, Semax does not produce peripheral sympathetic activation (no elevated heart rate, no blood pressure spike), and does not cause the cognitive crash that follows stimulant clearance; the activation profile is smooth and terminates cleanly as the compound clears
• BDNF and NGF upregulation — cumulative nootropic effect — Semax consistently increases BDNF expression in hippocampal CA1, CA3, and dentate gyrus regions and in the prefrontal cortex in preclinical models; BDNF drives long-term potentiation, synaptic density, and the structural plasticity underlying memory consolidation and new learning; the practical consequence is that users experience improvements in memory encoding and retrieval, faster learning of new material, and enhanced working memory capacity that builds progressively over 2–3 weeks of daily use and persists 1–4 weeks post-cycle due to the durable nature of BDNF-driven synaptic changes; NGF upregulation additionally supports cholinergic neuron survival and function, contributing to the longer-term cognitive benefit
• Dopaminergic and serotonergic modulation — motivation and mood — Semax increases dopamine and serotonin turnover in the striatum, nucleus accumbens, and prefrontal cortex; the dopaminergic component drives the motivation, reward-seeking, and goal-directed behavior enhancement that users report as increased drive and task initiation; the serotonergic component contributes to mood stabilization and reduces the anhedonia or motivational flatness that may accompany high training loads, caloric deficit, or PCT; together these monoaminergic effects are the pharmacological basis for Semax's performance-enhancing profile beyond pure memory and attention
• Neuroprotection and recovery from cognitive stress — Semax has significant neuroprotective activity documented in ischemic stroke and traumatic brain injury models; it reduces the extent of neuronal apoptosis in hypoxic conditions, accelerates functional recovery of motor and cognitive deficits, and promotes neurogenesis in damaged regions; in performance contexts, this translates to accelerated cognitive recovery from periods of severe sleep deprivation, high training stress, or CNS fatigue; it is the most appropriate peptide for athletes in phases of high-volume training where cognitive degradation from accumulated fatigue is a concern
• No HPTA interaction — full hormonal protocol compatibility — Semax does not interact with androgen receptors, estrogen receptors, or the hypothalamus-pituitary-gonadal axis; LH, FSH, testosterone, E2, and SHBG are completely unaffected; it can be used during any AAS cycle, any SARM cycle, during PCT, or as a standalone compound without hormonal consequence; it is one of the most universally stackable compounds at Steroid Warehouse precisely because it adds cognitive enhancement without altering the endocrine management of any protocol it accompanies

Who It's For

• Athletes and performance users in high-demand cognitive phases — peak competition preparation, high-volume training, complex programming periods — the mental load of managing training, nutrition, recovery, and competitive demands simultaneously creates a cognitive burden that physically compromises performance in ways that are difficult to attribute to any single factor; Semax addresses this by maintaining and elevating cognitive capacity during exactly the periods when it is most taxed; it is the performance compound for the cognitive dimension of sport, complementing what AAS, SARMs, and peptides do for the physical dimension
• Users whose primary need is cognitive activation, drive, and motivation rather than anxiety relief — Semax is the correct choice when the dominant complaint is low motivation, mental flatness, reduced drive, poor focus, or cognitive fatigue; when anxiety, stress reactivity, or psychological tension is the dominant complaint, Selank Dragon Pharma is the appropriate first compound; the distinction matters because using Semax in an anxious, overstimulated user may amplify anxiety rather than improve cognitive performance, while Selank in a low-motivation, cognitively flat user provides insufficient activation
• What differentiates Semax from similar alternatives: vs Selank Dragon Pharma — Selank is the anxiolytic, calming, sedation-free counterpart from the same Russian peptide program; both upregulate BDNF and improve cognition, but through different receptor pathways and with opposite experiential profiles; Semax drives and activates, Selank calms and stabilizes; the classical pairing is Selank morning (anxiety floor, sustained calm focus) combined with Semax as needed for acute cognitive activation and drive; the stack exploits the complementary mechanisms of both compounds without redundancy; users with both anxiety and motivation deficits should start with Selank, stabilize the anxiety component, then add Semax for the activation layer
• Users who should choose something else: users with pre-existing anxiety, high stress reactivity, or a history of stimulant-induced anxiety should start with Selank rather than Semax, or use Selank + Semax only after confirming tolerance to Semax's activating profile; users whose primary need is sleep improvement rather than daytime performance should start with DSIP Dragon Pharma; users expecting anabolic, androgenic, or fat-loss effects should use the appropriate compound class — Semax has no activity in those domains

Semax vs Alternatives

Dosing & Reconstitution

Side Effects & Management

Semax has a minimal side-effect profile at standard doses. Most adverse effects are mild, dose-dependent, and resolve without intervention.

Bloodwork Monitoring

Semax requires no dedicated bloodwork panel. The compound has no hepatic, renal, endocrine, or hematological effects at standard doses.

Cycle Structure

Practical Summary

References